Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-7249 and SHR-1918 in severe hypertriglyceridemia at high risk of acute pancreatitis
CTR20255011Phase 2Active
- Sponsor
- Tuojie Biotech
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-7249, SHR-1918 in hypertriglyceridemia, acute pancreatitis (AP), sponsored by Tuojie Biotech. Started Feb 2026; status: active.
02
Drugs
HRS-7249SHR-1918
03
Conditions
hypertriglyceridemiaacute pancreatitis (AP)
Beyond the preview
Go deeper on CTR20255011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255011.